Pfizer raises its 2026 performance forecast due to strong demand for its anticoagulant Eliquis

Reuters, November 3 - Pfizer Inc (PFE.N) raised its annual profit and revenue forecasts on Tuesday, primarily due to strong demand for its anticoagulant drug Eliquis.

The US pharmaceutical company expects full-year sales to reach $62 billion to $64 billion, up from its previous forecast of $60.5 billion to $62.5 billion. The company expects adjusted earnings per share for this year to be $2.95 to $3.05, compared to its previous forecast of $2.80 to $3.00 per share.

Previously, analysts on average expected annual earnings per share of $2.96, and 2026 revenue of $62.17 billion.

(To assist non-English speakers, Reuters has automated translation of its report into several other languages. As automated translation may contain errors or may not capture the required context, Reuters does not guarantee the accuracy of the automated translation text and provides it solely for the convenience of readers. Reuters accepts no liability for any damage or loss arising from the use of automated translation features.)